UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis : vimarsana.com

FDA approval of ZILBRYSQ® has been granted for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody-positive1ZILBRYSQ is the first...

Related Keywords

Smyrna , Izmir , Turkey , Japan , Brussels , Bruxelles Capitale , Belgium , Canada , Australia , Japanese , Australian , Daphne Teo , Jim Baxter , Antje Witte , Jamesf Howard , Howard Jf Jr , Eculizumab Soliris , Jean Christophe Tellier , Laurent Schots , Iris Loew Friedrich , Samantha Masterson , Australian Therapeutic Goods Administration , Health Canada , Twitter , Ucb Inc , Global Rare Disease Communications , Us Rare Disease Communications , National Institute Of Neurological Disorders , Group Of Companies , Japanese Ministry Of Health , European Union , European Medicines Agency , Myasthenia Gravis Foundation Of America , National Library Of Medicine , Committee For Medicinal Products Human Use , Drug Administration , Corporate Communications , Alexion Pharma Canada Corporation , Euronext Brussels , Lancet Neurology , Distinguished Professor , Neuromuscular Disease , Allied Health , North Carolina , Chapel Hill School , Chief Executive Officer , Myasthenia Gravis Foundation , Priority Review , Myasthenia Gravis Activities , Daily Living , Quantitative Myasthenia Gravis , Executive Vice President , Chief Medical Officer , Medicinal Products , Human Use , Japanese Ministry , Myasthenia Gravis , Myasthenia Gravis Composite , Myasthenia Gravis Quality , Biologic License Application , Safety Information , Patient Safety Card , Patient Guide , Prescribing Information , Medication Guide , Boxed Warning , Dose Prefilled , Novel Drug , Neurological Disorders , Gravis Fact , Accessed October , Expert Opin Investig , Clinical Review Report , Gravis Foundation , Markets ,